Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Karnak Technologies LLC is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. Prosecution is highly focused, involving 1 distinct examiner and 1 distinct art unit. This narrow footprint suggests a specific technical focus for the company's intellectual property efforts in the life sciences sector, where specialized art units often handle distinct biological or pharmaceutical classifications.
The busiest examiner for this portfolio is JANET JOSEPH, who is responsible for 1 pending office action. Since there is only 1 distinct examiner and 1 distinct art unit, the company's prosecution experience is currently limited to a single point of contact at the USPTO. Success for the 1 pending office action will depend on addressing the specific requirements of this examiner within the Biotechnology & Pharmaceuticals field. The lack of diversity across examiners or art units means that any delays encountered with the 1 distinct examiner will directly affect the total progress of the company's active patenting efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOSEPH, JANET | 1 | 40.0% | +51.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18013105 | PHARMACEUTICAL COMPOSITIONS FOR IMPROVED DELIVERY OF THERAPEUTIC LIPOPHILIC ACTIVES | JOSEPH, JANET | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18013105 | PHARMACEUTICAL COMPOSITIONS FOR IMPROVED DELIVERY OF THERAPEUTIC LIPOPHILIC ACTIVES | JOSEPH, JANET | 1611 | §103DP | Final Rejection | — | Pending | Dec 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial